ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
Applicability of ESPGHAN Biopsy-Free Guidelines for Celiac Disease Diagnosis: Insights from Türkiye.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: The biopsy-free diagnostic approach for celiac disease (CD) in children, recommended by ESPGHAN guidelines, is not widely implemented in pediatric gastroenterology centers across Türkiye. This study aimed to retrospectively evaluate patients who met ESPGHAN biopsy-free criteria but were nonetheless diagnosed through biopsy. Materials and Methods: Of 180 pediatric patients diagnosed with CD in the authors' department over 5 years, 79 (43.8%) met the ESPGHAN biopsy-free criteria. All patients underwent routine biopsies of the duodenum, bulb, antrum, corpus, and esophagus at diagnosis. Clinical presentations, celiac serology, and endoscopic and histopathological findings were retrospectively analyzed. Results: The mean age at diagnosis was 7.48 ± 4 years (range, 2-17; M/F: 38/41). Presenting symptoms included growth failure (32.9%), abdominal pain (22.8%), constipation (8.9%), diarrhea (7.6%), anemia (6.3%), vomiting (5%), and elevated liver enzymes (1.3%). Fourteen patients (17.7%) were diagnosed via screening; 9 (64.3%) had type 1 diabetes. Endoscopy findings were consistent with CD in 77 patients; 2 had normal results. Non-celiac endoscopic findings were seen in 19 patients. Histopathology confirmed Marsh 3 lesions in 78 patients; 1 had normal findings, with tTG IgA levels normalizing at a 4-month follow-up. The positive predictive value of biopsy-free criteria was 98.7%. Non-celiac findings (in 24 patients) included Helicobacter pylori gastritis (n = 7) and eosinophilic esophagitis (n = 2). Conclusion: The biopsy-free diagnostic approach accurately identifies CD in most cases but may miss treatable conditions like eosinophilic esophagitis or H. pylori infection, especially in endemic regions. Misdiagnoses, though rare, highlight the need for careful evaluation in populations with diverse clinical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.